1[1]Cairns JA. Randomised trial of outcome after myocardialInfarction in pa tients with frequent or repetitive ventricular premature depolarisation:CAMIAT [J]. Lancet, 1997,349:675
2[2]Singh SN. Amiodarone in patients with congestive heart failure and symp tomatic ventricular arrythmia[J]. N Engl J Med, 1995,33:77
3[3]Chuang CL, Chem MS, Chang SC, et al. Amiodarone toxicity in a patient with simultaneous involvement of cornea, thyroid gland, and lung[ J]. Am J Med Sci,2000,320(1) :64
4[4]Loh KC. Amiodarone-induced thyroid disorders: a clinical review[J]. Postgrad Med J,2000,76(893): 133
6[1]Remme WJ,Kruyssen HA,Look MP,et al.Hen-odynamic effects and tolerability of intravenous amiodarone in patients with impaired left ventricular function[J].Am Heart J,1991,122(1):96-103.
7[2]Myerburg RJ,Mitrai R,Interian JRA,et al.Evaluation of pharmacological and device therapy for the management of life threatening arrhythmias[J].Eur Heart J,1999,Supply:21.
8[4]Yeng.Propafenone mexiletime combone for the treatent of quesationed ventncular tachyeardia[J].TACC,1997,20(1):14.
9[2]张七一,曲彦.实用心血管药物治疗学[M].济南:山东科学技术出版社,2006:56-57.
10Myerburg RJ,Mitrani R,Interian JRA,et al.Eraluation of Pharmacologyical and device therapy for the management of life threatening arrhythmias[J].Eur Heart J,1999,(1):21.
